PhRMA Taps Former House Leader Eric Cantor as New CEO

The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading U.S. drug lobby group, announced Tuesday it has appointed former U.S. House Majority Leader Eric Cantor as its next president and chief executive officer. Cantor is set to take the helm on November 9, succeeding Stephen J. Ubl.

Leadership Transition

Cantor will replace Ubl, who has led the influential trade organization since 2015. In a statement, PhRMA confirmed that Ubl will remain with the group as a strategic adviser until mid-January 2027 to ensure a smooth transition.

The appointment brings a high-profile political figure to the forefront of the pharmaceutical industry's lobbying efforts. Rob Davis, PhRMA board chair and CEO of Merck, noted Cantor's deep experience in business, policy, and politics as key assets for the role.

Cantor's Political Background

Cantor served in the U.S. House of Representatives from 2000 to 2014, rising to the position of House Majority Leader. During his tenure, he was involved in key healthcare legislation, which PhRMA highlighted in its announcement.

Ad

The organization credited Cantor with supporting several legislative priorities for the industry, including:

• The Medicare Part D prescription drug program
• Funding for rare pediatric disease research
• The 21st Century Cures Act

Navigating Industry Headwinds

Cantor's appointment comes as the pharmaceutical sector continues to face significant political and regulatory pressure. During Ubl's leadership, the industry contended with persistent scrutiny from both presidential administrations and lawmakers regarding prescription drug pricing, market access, and federal regulation. Cantor's extensive background in Washington is seen as a strategic move to navigate this challenging environment.